In hemophilia A, both co-delivery of FVIII with OPLS and tolerogenic nanoparticle vaccination with FVIII encapsulated in phosphatidylserine liposomes led to a reduction in anti-drug antibodies toward FVIII in mice (207, 208), and antigen-containing phosphatidylserine liposomes reduced disease incidence in a model of T1D (209). The gene discussed is F8; the disease is hemophilia A.